Annual report pursuant to section 13 and 15(d)

Statement of Changes in Stockholders' Equity (Deficit)

v2.3.0.11
Statement of Changes in Stockholders' Equity (Deficit) (USD $)
Common Stock
Additional Paid-In Capital
Deficit Accumulated During the Development Stage
Total
Beginning Balance, amount at Aug. 23, 2009 $ 0 $ 0 $ 0 $ 0
Beginning Balance, shares at Aug. 23, 2009 0      
Issuance of common stock, shares 10,000,000      
Issuance of common stock, amount 10,000     10,000
Net loss     (137,821) (137,821)
Ending Balance, amount at Dec. 31, 2009 10,000 0 (137,821) (127,821)
Ending Balance, shares at Dec. 31, 2009 10,000,000      
Issuance of common stock, shares 41,236      
Issuance of common stock, amount 41 31,195   31,236
Stock based compensation   122   122
Issuance of common stock to acquire Boston Therapeutics, Inc. 4,000,000      
Issuance of common stock to acquire Boston Therapeutics, Inc. 4,000 874,647   878,647
Net loss     (248,295) (248,295)
Ending Balance, amount at Dec. 31, 2010 14,041 905,964 (386,116) 533,889
Ending Balance, shares at Dec. 31, 2010 14,041,236      
Issuance of common stock, shares 2,091,470      
Issuance of common stock, amount 2,091 520,906   522,997
Issuance of common stock in exchange for consulting services 90,500      
Issuance of common stock in exchange for consulting services 91 45,159   45,250
Stock based compensation   149,727   149,727
Net loss     (827,168) (827,168)
Ending Balance, amount at Dec. 31, 2011 $ 16,223 $ 1,621,756 $ (1,213,284) $ 424,695
Ending Balance, shares at Dec. 31, 2011 16,223,206